Rapid effects of different lipid-lowering drugs on PCSK9 in humans-Reference-Cited by-同舟云学术

Rapid effects of different lipid-lowering drugs on PCSK9 in humans

Published:2013-10-01 Issue:5 Volume:8 Page:519-524
ISSN:1758-4299
Container-title:Clinical Lipidology
language:en
Short-container-title:Clinical Lipidology

Author:

Liu Jun¹,Guo Yuan-Lin¹,Xu Rui-Xia¹,Li Jian-Jun¹

Affiliation:

1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,Endocrinology, Diabetes and Metabolism

Link

https://www.tandfonline.com/doi/pdf/10.2217/clp.13.55

Reference23 articles.

1. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis 216, 258–265 (2011). ▪ Excellent review of PCSK9 and its clinical significance.

2. Lagace TA, Curtis DE, Garuti R et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116, 2995–3005 (2006).

3. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid. Res. 49, 394–398 (2008). ▪▪ The first study investigating the effects of statins on PCSK9 in humans.

4. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J. Lipid. Res. 51, 2714–2721 (2010).

5. Awan Z, Seidah NG, MacFadyen JG et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER Trial. Clin. Chem. 58, 183–189 (2012).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond;International Journal of Molecular Sciences;2022-01-19

2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis;Lipids in Health and Disease;2021-01-18

3. Diallyl disulfide improves lipid metabolism by inhibiting PCSK9 expression and increasing LDL uptake via PI3K/Akt-SREBP2 pathway in HepG2 cells;Nutrition, Metabolism and Cardiovascular Diseases;2021-01

4. The Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Cardiovascular Homeostasis: A Non-Systematic Literature Review;Current Cardiology Reviews;2017-10-23

5. Extended-release Formulation Attenuates the Impacts of Fluvastatin on Serum PCSK9 Levels in Humans;Letters in Drug Design & Discovery;2017-06-30